This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
We thank Finsterer for the thoughtful commentary on the case, “A case report of semaglutide induced sarcopenia: causes of fatigue in older adults” [1,2].
Sarcopenia is a well-defined clinical syndrome characterized by low muscle mass, reduced muscle strength, and/or impaired physical performance, as outlined by the Asian Working Group for Sarcopenia 2019 consensus, and it is a clinical diagnosis [3]. Its recognition is increasingly relevant in clinical practice, particularly among older adults with comorbidities such as type 2 diabetes, in whom prevalence is notably elevated [4]. Identifying red-flag symptoms, such as weight loss, general weakness, fatigue, falls, mobility impairment, loss of energy, and difficulties in physical activities or activities of daily living, is essential for screening and early detection of sarcopenia [3].
Importantly, emerging evidence suggests a potential association between glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide, and accelerated loss of muscle mass even in the absence of overt muscle weakness [5]. Among 220 patients treated with semaglutide and 212 controls, 27.7% of the semaglutide-treated group showed a significantly reduced body mass index and muscle mass compared with controls [6]. However, no dedicated controlled trials have evaluated the effects of GLP-1RAs on skeletal muscle mass or muscle strength in older adults with sarcopenia. While dedicated controlled trials in older adults with sarcopenia are needed, real-world observations underscore the importance of vigilant monitoring of this population [5].
The patient was diagnosed with mild ocular myasthenia gravis in 2017 based on characteristic clinical findings of intermittent ptosis, absence of ophthalmoplegia, and the presence of antiacetylcholine receptor antibodies. The condition was managed conservatively with specialized ophthalmic care without immunosuppressive therapy [7]. Repeated neurological evaluations, including recent electromyography, showed no evidence of progression to generalized myasthenia gravis or thymoma. The long-term stability of ocular symptoms, along with the lack of systemic progression, supported the diagnosis made by the treating neurologist. Collectively, the patient’s non-progressive ocular presentation, absence of systemic mitochondrial features, and improved clinical symptoms following rehabilitation and semaglutide dose reduction made chronic progressive external ophthalmoplegia unlikely [8].
Extensive investigations were performed to exclude other potential causes of fatigue and muscle wasting. With respect to diabetic neuropathy, the patient exhibited no clinical symptoms or signs suggestive of peripheral neuropathy, such as sensory loss, neuropathic pain, or distal weakness; therefore, electrodiagnostic testing was not indicated. Regarding a potential paraneoplastic syndrome, the patient’s history of localized prostate cancer had been treated with curative intent, and recent surveillance imaging using positron emission tomography revealed no evidence of recurrence or metastasis. Given the absence of neurological progression or systemic symptoms, paraneoplastic antibody testing was not clinically recommended. Furthermore, comprehensive blood work, cardiopulmonary exercise testing, echocardiography, and brain imaging effectively ruled out metabolic, cardiovascular, respiratory, and central neurological etiologies.
The temporal relationship between symptom onset and semaglutide use is noteworthy. In the present case, semaglutide therapy was initiated in 2022 following a recent increase in the patient’s hemoglobin A1c level to 8.4%, as recommended by an endocrinologist. The patient did not report any symptoms consistent with peripheral neuropathy. Treatment began with injectable semaglutide, which was administered for 6 months before transitioning to an oral formulation for 12 months because of fatigue. The chronological sequence of events is shown in Figure 1. Over the last 8 months, the patient reported notable weight loss. Following multidisciplinary evaluation, the patient was referred to a sports medicine clinic for further assessment of persistent fatigue. Sarcopenia was subsequently identified as a probable underlying cause. A tailored rehabilitation program was initiated in conjunction with a reduction in the semaglutide dosage, after which clear clinical improvement was observed. Importantly, within 4 months, the patient demonstrated measurable improvements in muscle mass, grip strength, and walking speed, supporting a plausible causative role of semaglutide in the absence of other identifiable etiologies.
We fully acknowledge that rehabilitation is a cornerstone of sarcopenia management [3]. However, the concurrent timing of clinical improvement following dose reduction suggests that semaglutide likely played a contributory role. Notably, the patient continued semaglutide therapy at a reduced dose alongside sustained exercise intervention, suggesting that medication adjustment and proactive physical rehabilitation can be effectively integrated into long-term management.
In conclusion, this case underscores the importance of monitoring for sarcopenia in older adults treated with GLP-1 receptor agonists such as semaglutide. Although exhaustive exclusion of all possible etiologies remains the ideal standard, clinical practice often requires balanced judgment based on available evidence, clear temporal associations, and observed responses to intervention. We maintain that semaglutide may contribute to muscle loss in susceptible individuals and emphasize that early recognition and multidisciplinary management, including individualized exercise and nutritional support, are essential to mitigate functional decline.
Article Information
Conflict of interest
No potential conflict of interest relevant to this article was reported.
Funding
None.
Data availability
All data is available from the corresponding authors.
Author contribution
All the work for the preparation of this letter was done by Azwan Aziz Mohamad.
Figure. 1.
Clinical timeline of the patient. The figure illustrates the chronological sequence of key diagnoses, interventions, and assessments from 2017 to August 2024. It highlights the diagnosis of ocular myasthenia gravis (MG) (2017), localized prostate carcinoma (2019), initiation of injectable semaglutide (August 2022), its conversion to an oral formulation (March 2023), and the subsequent worsening of fatigue leading to referral to Sports Medicine (February 2024). The timeline culminates in the assessment and diagnosis of sarcopenia (April 2024), followed by a structured rehabilitation program and reduction of semaglutide dose, which led to improvements in symptoms, muscle mass, strength, and physical function (August 2024). ACR, acetylcholine receptor; PET, positron emission tomography; HbA1c, hemoglobin A1c; CPET, cardiopulmonary exercise testing.
References
1. Finsterer J. Semaglutide can only be responsible for exercise intolerance and muscle wasting after all other causes have been carefully excluded. Korean J Fam Med 2026;47:93-4.
6. Ren Q, Zhi L, Liu H. Semaglutide therapy and accelerated sarcopenia in older adults with type 2 diabetes: a 24-month retrospective cohort study. Drug Des Devel Ther 2025;19:5645-52.
Beyond Weight Loss: A Geriatric Perspective on GLP‐1 RAs in Older Adults With Obesity Sofia Mendes‐Piteira, Mariana Alves Obesity.2026; 34(11): 2007. CrossRef
Sarcopenia considerations when prescribing glucagon-like peptide-1 agonists to older adults
Figure. 1. Clinical timeline of the patient. The figure illustrates the chronological sequence of key diagnoses, interventions, and assessments from 2017 to August 2024. It highlights the diagnosis of ocular myasthenia gravis (MG) (2017), localized prostate carcinoma (2019), initiation of injectable semaglutide (August 2022), its conversion to an oral formulation (March 2023), and the subsequent worsening of fatigue leading to referral to Sports Medicine (February 2024). The timeline culminates in the assessment and diagnosis of sarcopenia (April 2024), followed by a structured rehabilitation program and reduction of semaglutide dose, which led to improvements in symptoms, muscle mass, strength, and physical function (August 2024). ACR, acetylcholine receptor; PET, positron emission tomography; HbA1c, hemoglobin A1c; CPET, cardiopulmonary exercise testing.
Figure. 1.
Sarcopenia considerations when prescribing glucagon-like peptide-1 agonists to older adults